-
Views
-
Cite
Cite
Sachiko Goto, In Vitro and in Vivo Antibacterial Activity of Moxalactam, an Oxa-β-Lactam Antibiotic, Reviews of Infectious Diseases, Volume 4, Issue Supplement_3, November-December 1982, Pages S501–S510, https://doi.org/10.1093/clinids/4.Supplement_3.S501
- Share Icon Share
Abstract
Moxalactam, a new synthetic β-lactam antibiotic, was evaluated for in vitro and in vivo antibacterial activity and was found to have a broad spectrum of activity against gram-positive and gram-negative bacteria. Moxalactam showed more potent activity than did' the cephalosporins tested against clinical gram-negative isolates, including cefazolin-resistant Enterobacteriaceae, glucose-nonfermenting bacteria, and Bacteroides fragilis. Moxalactam was the only β-lactam antibiotic of those tested (including nine penicillins and 15 cephalosporins) that was not affected by β-lactamase produced by 15 strains of 10 gram-negative species. The potent in vitro activity and high stability to β-Iactamase of moxalactam corresponded to lower ED50 (50% effective doses) required against intraperitoneal infections in mice due to various bacteria resistant to cefazolin, cefoxitin, or cefotiam. Furthermore, moxalactam showed the greatest therapeutic activity among the nine β-Iactam antibiotics tested in models of intraperitoneal mixed infection in mice with Escherichia coli and Pseudomonas aeruginosa.
- antibiotics
- pseudomonas aeruginosa
- penicillin
- cefoxitin
- cephalosporins
- glucose
- bacteroides fragilis
- cefazolin
- cefotiam
- enterobacteriaceae
- gram-negative bacteria
- gram-positive bacteria
- gram-positive bacterial infections
- gram-positive cocci
- gram-positive rods
- lactams
- moxalactam
- infections
- bacteria
- mice
- anti-bacterial agents
- escherichia coli
- coinfection
- intraperitoneal infusion